Ocugen’s India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report
India-based Bharat Biotech has completed the Phase 2 and 3 trials of COVID-19 vaccine, Covaxin, for use in 2 to 18 years. …
Bharat Biotech has Completed Phase 2 and 3 Clinical Trials of Covaxin for Use in Children 2 to 18 Years; Chairman Krishna Ella said Covaxin Production would Reach 55M Doses in October vs 35M in September
Live Mint
https://www.livemint.com/news/india/bharat-biotech-completes-covaxin-phase-2-3-clinical-trials-for-children-11632213730051.html
‘SAGE Meeting at WHO to take up [Ocugen Partner] Bharat Biotech Covaxin issue on October 5’ -Tweet From CNN Political Reporter
https://twitter.com/AmanKayamHai_/status/1438906591407837185?s=20
Ocugen Partner ‘Bharat Biotech awaits feedback from WHO for Covaxin emergency use’ -India’s Business Standard
https://www.business-standard.com/article/international/bharat-biotech-awaits-feedback-from-who-for-covaxin-emergency-use-121091700551_1.html
Where’s Ocugen Stock Headed Monday And Why?
Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Monday, after Bharat Biotech: a company partner, was given the nod for a COVID-19 vaccine by the World Health Organization. The company saw a large upward movement Monday morning.
Ocugen is trading up 16.81% at $8.28 Monday afternoon.
Why Are Ocugen Shares Surging On Monday?
According to sources, the World Health Organization (WHO) is likely to grant India's COVID-19 vaccine, Covaxin, for an emergency use listing (EUL) this week. Ocugen Inc (NASDAQ: OCGN) is the U.S. partner for the vaccine.
45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets.